Intelligence Feed event · Capital · 2026-09-25

    ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share

    Question

    ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share

    Direct answer

    ADARx Pharmaceuticals finalized terms for its upsized initial public offering, selling 26.25 million common shares at $17 each to secure approximately $446.3 million in gross capital. The late-stage siRNA therapeutics developer lists on Nasdaq under ticker symbol ADRX on September 25. The transaction represents one of the larger healthcare capital-raising events of the quarter.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-25
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share”, revision 1, evidence through 2026-09-25. https://marketontology.com/market-events/2026-09-25/adarx-pharmaceuticals-prices-upsized-446-3m-ipo-at-17-per-share-4a4ce6

    CAPITAL
    ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share
    ADARx Pharmaceuticals finalized terms for its upsized initial public offering, selling 26.25 million common shares at $17 each to secure approximately $446.3 million in gross capital. The late-stage siRNA therapeutics developer lists on Nasdaq under ticker symbol ADRX on September 25. The transaction represents one of the larger healthcare capital-raising events of the quarter.
    ADRX
    Impact
    72
    SEP 25
    SIG
    95%
    ADRX
    ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share
    ADARx Pharmaceuticals finalized terms for its upsized initial public offering, selling 26.25 million common shares at $17 each to secure approximately $446.3 million in gross capital. The late-stage siRNA therapeutics developer lists on Nasdaq under ticker symbol ADRX on September 25. The transaction represents one of the larger healthcare capital-raising events of the quarter.
    → Upsized equity issuance tests risk appetite for late-stage clinical biotech assets in a high-cost-of-capital environment.
    Impact
    ADARx Pharmaceuticals finalized terms for its upsized initial public offering, selling 26.25 million common shares at $17 each to secure approximately $446.3 million in gross capital. The late-stage siRNA therapeutics developer lists on Nasdaq under ticker symbol ADRX on September 25. The transaction represents one of the larger healthcare capital-raising events of the quarter.
    Affected
    ADRX
    Transmission
    Upsized equity issuance tests risk appetite for late-stage clinical biotech assets in a high-cost-of-capital environment.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ADRXinitial market trading valuation and secondary liquidity formationWatchintradayPriced 26.25M shares at $17 to raise $446.3M ahead of Nasdaq debut

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    ADRXWatch19.35 2026-09-25+3.82%-5.68%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month